Articles producció científica> Bioquímica i Biotecnologia

Current Research Therapeutic Strategies for Alzheimer's Disease Treatment

  • Datos identificativos

    Identificador: PC:1851
    Autores:
    Jaume FolchDmitry PetrovMiren EttchetoSonia AbadElena Sánchez-LópezM. Luisa GarcíaJordi OlloquequiCarlos Beas-ZarateCarme AuladellAntoni Camins
    Resumen:
    Filiació URV: SI
  • Otros:

    Autor según el artículo: Jaume Folch; Dmitry Petrov; Miren Ettcheto; Sonia Abad; Elena Sánchez-López; M. Luisa García; Jordi Olloquequi; Carlos Beas-Zarate; Carme Auladell; Antoni Camins
    Departamento: Bioquímica i Biotecnologia
    Autor/es de la URV: FOLCH LOPEZ, JAUME; Dmitry Petrov; Miren Ettcheto; Sonia Abad; Elena Sánchez-López; M. Luisa García; Jordi Olloquequi; Carlos Beas-Zarate; Carme Auladell; Antoni Camins
    Palabras clave: Amyloid beta protein
    Resumen: Alzheimer's disease (AD) currently presents one of the biggest healthcare issues in the developed countries. There is no effective treatment capable of slowing down disease progression. In recent years the main focus of research on novel pharmacotherapies was based on the amyloidogenic hypothesis of AD, which posits that the beta amyloid (Aβ) peptide is chiefly responsible for cognitive impairment and neuronal death. The goal of such treatments is (a) to reduce Aβ production through the inhibition of β and γ secretase enzymes and (b) to promote dissolution of existing cerebral Aβ plaques. However, this approach has proven to be only modestly effective. Recent studies suggest an alternative strategy centred on the inhibition of the downstream Aβ signalling, particularly at the synapse. Aβ oligomers may cause aberrant N-methyl-D-aspartate receptor (NMDAR) activation postsynaptically by forming complexes with the cell-surface prion protein (PrPC). PrPC is enriched at the neuronal postsynaptic density, where it interacts with Fyn tyrosine kinase. Fyn activation occurs when Aβ is bound to PrPC-Fyn complex. Fyn causes tyrosine phosphorylation of the NR2B subunit of metabotropic glutamate receptor 5 (mGluR5). Fyn kinase blockers masitinib and saracatinib have proven to be efficacious in treating AD symptoms in experimental mouse models of the disease.
    Grupo de investigación: Farmacobiologia Cel.lular
    Áreas temáticas: Bioquímica i biotecnologia Bioquímica y tecnología Biochemistry and technology
    Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
    ISSN: 2090-5904
    Fecha de alta del registro: 2016-07-27
    Volumen de revista: 2016
    Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
    Enlace a la fuente original: https://www.hindawi.com/journals/np/2016/8501693/
    URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
    DOI del artículo: 10.1155/2016/8501693
    Entidad: Universitat Rovira i Virgili
    Año de publicación de la revista: 2016
    Página inicial: Art.num. 8501693
    Tipo de publicación: Article Artículo Article
  • Palabras clave:

    Alzheimer, Malaltia d' -- Cura i tractament
    Beta-proteïna amiloide
    Amyloid beta protein
    Bioquímica i biotecnologia
    Bioquímica y tecnología
    Biochemistry and technology
    2090-5904
  • Documentos:

  • Cerca a google

    Search to google scholar